Investigation of Pharmacokinetics, Safety, and Tolerability of Vilaprisan (BAY1002670) in Subjects With Hepatic Impairment (Classified as Child-Pugh A or B) Compared to Sex, Age, and Weight-matched Healthy Subjects Following a Single Oral Dose
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2018
At a glance
- Drugs Vilaprisan (Primary)
- Indications Uterine leiomyoma
- Focus Pharmacokinetics
- Sponsors Bayer
- 10 Oct 2018 Results presented at the American Society for Reproductive Medicine Scientific Congress 2018
- 17 Aug 2017 Status changed from recruiting to completed.
- 06 Apr 2017 Status changed from not yet recruiting to recruiting.